Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer-related Cognitive Dysfunction Adnexal Diseases Cytomegaloviral Infection Cytomegalovirus Infections DNA Virus Infections Endocrine Gland Neoplasms Endocrine System Diseases Fallopian Tube Carcinoma Fallopian Tube Diseases Fallopian Tube Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Herpesviridae Infections Infections Neoplasms Neoplasms by Site Ovarian Carcinoma Ovarian Diseases Ovarian Neoplasms Primary Peritoneal Carcinoma Urogenital Diseases Urogenital Neoplasms Virus Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18
Ability to read and write in English
Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube)
Receiving care from providers at Mayo Clinic
Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence)

Exclusion criteria

Pregnant at the time of study participation
Inability to provide informed written consent
History of dementia, stroke, brain tumors or other condition which may impair cognitive functioning

Treatment and study plan

Non-Interventional Study

Other

Non-Interventional Study

Primary outcomes

Using saliva and blood samples to remotely monitor cytomegalovirus (CMV) infection

Time frame: Baseline

Assessed through collection and comparison of blood and saliva samples collected from individuals receiving treatment for ovarian cancer. Samples may be collected in clinic or at home following study enrollment. Saliva will be self-collected using Oragene OGR-600 kits. Blood samples will be collected at the time of another scheduled clinic blood draw (Aim 1) or at home through a home phlebotomy service (Aim 2).

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

National Cancer Institute (NCI)

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Mar 11, 2025
Registry last updated: Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting